Benznidazole - Insud Pharma

Drug Profile

Benznidazole - Insud Pharma

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chemo Group
  • Developer Drugs for Neglected Diseases Initiative Foundation; Exeltis USA; Insud Pharma; Mundo Sano
  • Class Acetamides; Antiprotozoals; Imidazoles
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chagas disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chagas disease

Most Recent Events

  • 12 Jan 2018 Launched for Chagas' disease (In children) in USA (PO) before January 2018
  • 01 Sep 2017 Chemical structure information added
  • 29 Aug 2017 Benznidazole receives tropical disease priority review voucher for Chagas's disease from the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top